ReviewCancer science2015
Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
Tsukasa Seya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
42 papers cite it
this papercites it